Surgepays Inc SURG.OQ SURG.O is expected to show a fall in quarterly revenue when it reports results on November 12 for the period ending September 30 2024
The Bartlett Tennessee-based company is expected to report a 74.7% decrease in revenue to $8.642 million from $34.16 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Surgepays Inc is for a loss of 27 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Surgepays Inc is 5.50, above its last closing price of $1.52.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Jun. 30 2024 | -0.09 | -0.07 | -0.66 | Missed | -842.9 |
Jan. 1 2024 | 0.14 | 0.15 | 0.07 | Missed | -53.3 |
Dec. 31 2023 | 0.41 | 0.41 | 0.19 | Missed | -53.3 |
Sep. 30 2023 | 0.28 | 0.29 | 0.49 | Beat | 71.9 |
Jun. 30 2023 | 0.15 | 0.16 | 0.40 | Beat | 158.1 |
Mar. 31 2023 | -0.03 | -0.03 | 0.31 | Beat | 1,133.3 |
Dec. 31 2022 | -0.19 | -0.11 | 0.25 | Beat | 317.4 |
Jan. 1 0001 | 0.29 | 0.29 | -0.12 | Missed | -141.4 |
This summary was machine generated November 9 at 00:43 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。